Ganciclovir

• Description:

  Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC50 of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain[1][2][3].

• Product Name Alternative:

  BW 759; 2'-Nor-2'-deoxyguanosine

• UNSPSC:

  12352005

• Hazard Statement:

  H360

• Target:

  Antibiotic; CMV; HSV; Nucleoside Antimetabolite/Analog

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ganciclovir.html

• Concentration:

  10mM

• Purity:

  99.89

• Solubility:

  DMSO : 60 mg/mL (ultrasonic) |H2O : 1.67 mg/mL (ultrasonic)

• Smiles:

  O=C1NC (N) =NC2=C1N=CN2COC (CO) CO

• Molecular Formula:

  C9H13N5O4

• Molecular Weight:

  255.23

• Precautions:

  H360

• References & Citations:

  [1]Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65 (4) :399-403.|[2]Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115.|[3]Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23 (1) :5-12.|[4]Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4.|[5]Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39 (3) :189-197.|[6]Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39 (4) :597-638.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  HSV-1; HSV-2

• Citation 01:

  Antiviral Res. 2021 Sep:193:105124.|bioRxiv. 2025 Nov 13:2025.11.11.687828.|Brain Behav Immun. 2019 Aug:80:394-405.|Cell. 2020 Nov 25;183 (5) :1402-1419.e18.|Cell. 2025 Apr 3;188 (7) :1828-1841.e15.|Cells. 2019 Dec 20;9 (1) :31.|Eur J Pharm Sci. 2019 Jan 15:127:29-37.|J Nanobiotechnology. 2022 Jul 20;20 (1) :340.|J Virol. 2017 Jan 18;91 (3) . pii: e02152-16.|Microchem J. 2021, 106587.|Pharmaceuticals (Basel) . 2025 Oct 16;18 (10) :1560.|Pharmaceutics. 2023 Nov 27;15 (12) :2680.|Pharmacol Res Perspect. 2020 Apr;8 (2) :e00575.|PLoS Pathog. 2024 Apr 16;20 (4) :e1012141.|Sci Data. 2022 Oct 8;9 (1) :610.|Stem Cells. 2025 Jun 24;43 (7) :sxaf032.|Trends Biotechnol. 2025 Aug 29:S0167-7799 (25) 00316-6.|Biochem Pharmacol. 2022 Mar:197:114917.|bioRxiv. 2023 Sep 20.|Nat Commun. 2024 Apr 17;15 (1) :3311.|Nat Neurosci. 2024 Aug;27 (8) :1522-1533.|Research Square Print. 2023 Mar.

• CAS Number:

  82410-32-0